China-Biotics, Inc., ("China-Biotics", "the Company"), a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, today announced that it attended in the 2009 National Exchange Seminar on Probiotics and Their Technical Applications (the "National Exchange Seminar") through September 20-22, in Shenzhen, China.

The Seminar was organized by the State Food and Drug Administration in China ("SFDA"). The keynote presentation topics focused on industry regulation and standards of probiotics applications, probiotics function and human health, probiotics technical research and product development, and probiotics testing method and devices. Probiotics-based product manufacturers and medical institutions were invited to the Seminar, including BioTime, Nestle China, Yakult China, the National Center for Disease Control and Prevention, Chongqing Medical School, Dalian Medical School, and etc. Kai Ma, PhD., Chief Scientist of China-Biotics, presented the topic of "Probiotics Testing Standards and Industry Standards" at the Seminar. Dr. Ma has long been involved in China's probiotics application standards proposal drafting activities. Effective June 1, 2009, China's new umbrella food safety law for the first time included probiotics applications as part of regulated food production throughout China.

"We are very pleased to have attended the National Exchange Seminar to share our experience and expertise with other probiotics specialists," said Mr. Jinan Song, Chairman and Chief Executive Officer of China-Biotics. "We believe that the new food safety law is yet another milestone for our industry since all manufacturers now have to produce under much more stringent standards. As a leading probiotics provider, China-Biotics has already set strict internal standards in its manufacturing procedures that are higher than the national level."

About China-Biotics, Inc.

China-Biotics, Inc. ("China-Biotics," "the Company"), a leading manufacturer of biotechnology products and supplements, engages in the research, development, marketing and distribution of probiotics dietary supplements. Through its wholly owned subsidiary, Shanghai Shining Biotechnology Co., Ltd., the Company has operations in Shanghai. Its proprietary product portfolio contains live microbial nutritional supplements under the "Shining" brand. Currently, the products are sold OTC through large distributors to pharmacies and supermarkets in Shanghai, Jiangsu, and Zhejiang. China-Biotics plans to launch 300 Shining brand retail outlets in major cities in China. Currently, China-Biotics is strategically expanding its production capacity of probiotics to meet growing demand in the bulk additive market. For more information, please visit http://www.chn-biotics.com .

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such factors include, but are not limited to, the Company's ability to market existing and new products, ability to access to capital for expansion, and changes from anticipated levels of sales, future national or regional economic and competitive conditions, market acceptance of its retail store concept, changes in relationships with customers, dependence on its flagship product profits and other factors detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.